Rapport Therapeutics, Inc.
RAPP
$9.99
-$0.48-4.59%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -20.44% | -13.93% | 3.22% | 20.06% | -67.68% |
| Total Depreciation and Amortization | -6.15% | 18.72% | 5.29% | 36.84% | 186.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.08% | 185.00% | -18.05% | -79.10% | 591.76% |
| Change in Net Operating Assets | -132.29% | 381.13% | -287.80% | 96.10% | -262.40% |
| Cash from Operations | -40.09% | 12.00% | -0.39% | 7.17% | -70.08% |
| Capital Expenditure | -28.76% | -61.43% | 85.52% | 9.79% | 25.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -33.69% | 160.79% | 50.16% | -159.80% | 47.10% |
| Cash from Investing | -34.13% | 160.20% | 50.48% | -155.46% | 46.70% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -14.29% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 200.00% | -111.19% |
| Cash from Financing | -28.57% | 100.50% | -100.87% | 150.32% | 45,570.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -95.43% | 124.69% | -297.37% | 771.71% | 104.62% |